Refine by
Molecular Target Articles & Analysis: Older
32 news found
Research on molecular targeted therapy for tumors is increasing, and new targeted therapeutic agents are emerging. ...
The comprehensive range of services includes drug screening, virtual screening, molecular docking, conformational sampling, and drug property prediction. ...
Bayer is advancing its oncology R&D efforts in three scientific areas that have the potential to address unmet needs in cancer patients: next-generation Immuno-Oncology, Targeted Radionuclide Therapies and Precision Molecular Oncology. Data from all three areas of scientific focus will be showcased during this year’s meeting. ...
ByBayer AG
Tulmimetostat is an oral, investigational next-generation selective dual inhibitor of EZH2 and EZH1 designed to improve on first generation EZH2 inhibitors via increased potency, longer residence time on target and a longer half-life. The data were presented during poster sessions at the 34th Symposium on Molecular Targets and Cancer Therapeutics ...
This adds to the growing body of evidence for the need to study more molecular targets per sample to provide actionable insights. “In liquid biopsy clinical research, we see a desire to conduct more near-patient testing with faster time to results, lower costs, higher sensitivity, and a highly standardized process from sample preparation to results,” ...
This huge corpus of data on one protein family provides a trove of information on how antibodies interact with their antigen targets at the atomic level. Our knowledge of antibody structure-function relationships has allowed the engineering of antibodies to improve characteristics such as antigen affinity and effector function. ...
About BOC Sciences As a leading manufacturer and service provider in drug research and discovery, BOC Sciences is fully competent and dedicated to serving one-stop Proteolysis Targeting Chimeric (PROTAC) based molecular drug discovery, which has become a promising strategy in drug discovery. ...
In addition, the Accelerate Arc system is designed to eliminate the need for overnight culture incubation for current MALDI users, while reducing the likelihood of cross reactivity and potential false positive results that come with rapid multi-targeted molecular tests. For some labs, roughly 30% of molecular tests turn up as contaminants, ...
Establishment of new precision molecular oncology research center to drive development of novel targeted cancer therapies for patients with unmet medical need Strategic investment of $140M USD to expand presence in leading center of biotech innovation at Kendall Square in Cambridge Fostering close collaboration with scientists, enhancing global network of ...
ByBayer AG
About AB-2004 AB-2004 is a first-in-class, molecular therapeutic that targets the microbiome gut-brain axis and its role in co-occurring conditions associated with ASD. AB-2004 has a unique mechanism of action that selectively sequesters certain gut-derived metabolites before they enter the bloodstream and reach the brain. Axial believes this ...
“This combination of molecular markers, targeted macroscopic image-guided surgery/endoscopy and endomicroscopy represents a significant clinical milestone that we are about to embark ...
Food and Drug Administration (FDA) Adverse Event Reporting System back to molecular pathways and target profile data, the two proof-of-concept studies examined potential causes of cardiotoxicity and of colitis associated with well-known targeted cancer therapies. Using this analytical method, the authors developed hypotheses about different ...
AB-2004 is being studied as a potential new treatment for managing irritability associated with Autism Spectrum Disorder (ASD) in children and is the company’s lead gut-targeted, molecular therapeutic. The article, titled “Safety and target-engagement of an oral small molecule sequestrant in adolescents with Autism Spectrum Disorder: ...
Aclys has built a broad range of antibodies using its PILA™ platform to create targeted therapeutics for solid tumors. The agreement with Genmab recognizes the capability of the Aclys PILA platform to identify novel precision targets. ...
Advancement of first program from Axial platform into a randomized Phase 2b clinical trial signifies key milestone for company Trial is enrolling approximately 195 autistic adolescents at clinical trial sites in the United States, Australia and New Zealand Phase 2 trial is based on positive results from open-label Phase 1b/2a trial that demonstrated a favorable safety profile for AB-2004 as ...
Patients having surgery to remove one or more tumors will receive one dose of LB-100 prior to surgery and have blood and tumor tissue analyzed for the amount of LB-100 present and to determine whether the cells in the tumors show the biochemical changes expected to be present if LB-100 reaches its molecular target. The initial goal is to obtain this vital ...
Evox uses its proprietary DeliverEXTM technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. ...
Food and Drug Administration (FDA) of its investigational new drug (IND) application for lead candidate, AB-2004, a gut-targeted, molecular therapeutic for the treatment of irritability associated with ASD. ...
Molecular Health and the life science company Gen Era Diagnostics have signed a collaboration agreement to optimize the personalized treatment of patients with cancer. ...
Axial is advancing a pipeline of small molecule drugs with defined mechanisms of action that act on new targets to mitigate the impact of metabolites and bacteria in the gut linked to neurological disease pathology, progression, and symptoms. ...